HK Stock Market Move | LAEKNA-B(02105) surged over 14%, company accelerates the promotion of LAE102 clinical research and development, institutions are optimistic about its future commercial development.

LAEKNA-B (02105) rose more than 14%, as of press time, up 14%, at HKD 12.38, with a turnover of HKD 161 million. On the news front, Laike Pharmaceuticals previously announced that its self-developed LAE102 (ActRIIA monoclonal antibody) has made smooth progress in Phase I clinical trials targeting overweight/obesity in China: all 64 subjects (divided into 8 intravenous infusion and subcutaneous injection dose escalation queues) have completed dosing in the single-dose escalation (SAD) study. In November of last year, Laike Pharmaceuticals signed a clinical cooperation agreement with Lilly. With Laike Pharmaceuticals retaining the global rights to LAE102, Lilly will be responsible for and bear the costs of Phase I studies in the United States. A previous research report by China Great Wall pointed out that the company, focused on the development of innovative therapies for unmet clinical needs in cancer, is on track to commercialize its core pipeline products LAE002 and LAE001. The company's self-developed pipeline, represented by the muscle-building and fat-reducing drug LAE102, has good prospects for innovation. The bank is optimistic about the future commercial development of the company's products.